youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
ACAD:NASDAQ
ACADIA Pharmaceuticals Inc
$20.47
arrow_downward
-0.58%(-0.12) 1D
$20.21
arrow_downward
-1.27% (-0.26)bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ACAD...
Open
$20.71
High
$20.76
Low
$20.25
Mkt. cap
3.53B
Avg. vol.
2.04M
Volume
0.00
P/E ratio
9.25
52-wk high
$30.96
52-wk low
$18.39
EPS
$2.21
Beta
0.89
Shares outstanding
172.31M
No. of employees
797
Open
$20.71
High
$20.76
Low
$20.25
Mkt. cap
3.53B
Avg. vol.
2.04M
Volume
0.00
P/E ratio
9.25
52-wk high
$30.96
52-wk low
$18.39
EPS
$2.21
Beta
0.89
Shares outstanding
172.31M
No. of employees
797
News stories
From web sources and news partners
Profile
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California. Wikipedia
About ACADIA Pharmaceuticals Inc
CEOCatherine Owen Adams
Employees797
Founded1993
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteacadia.com
Analyst ratings
Based on 15 analysts giving stock ratings to ACAD in the past 3 months
Buy
Buy
10
Hold
5
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for ACAD in the last 3 months.
Highest
Current $20.47
$37.00 (+80.75%)
Average
$31.43 (+53.54%)
Lowest
$23.00 (+12.36%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ami Fadia Needham | Buy | Reiterated | $35.00 | +71% | 10/19/2026 |
Ashwani Verma UBS | Hold | Downgraded | $23.00 | +12.4% | 10/13/2026 |
Malcolm Hoffman BMO Capital | Buy | Maintained | $34.00 | +66.1% | 10/12/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | $31.00 | +51.4% | 10/09/2026 |
Brian Abrahams RBC Capital | Buy | Maintained | $36.00 | +75.9% | 10/08/2026 |
Ananda Ghosh H.C. Wainwright | Buy | Maintained | $33.00 | +61.2% | 09/25/2026 |
David Hoang Deutsche Bank | Buy | Reiterated | $31.00 | +51.4% | 09/25/2026 |
Sumant Kulkarni Canaccord Genuity | Buy | Reiterated | $36.00 | +75.9% | 09/25/2026 |
Jason Butler Citizens JMP | Buy | Maintained | $33.00 | +61.2% | 09/25/2026 |
Yigal Nochomovitz Citi | Buy | Maintained | $33.00 | +61.2% | 09/25/2026 |
Sean Laaman Morgan Stanley | Hold | Reiterated | $28.00 | +36.8% | 08/25/2026 |
Unknown Analyst Guggenheim | Hold | Maintained | - | - | 08/04/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $36.00 | +75.9% | 08/04/2026 |
Matthew Hershenhorn Oppenheimer | Hold | Maintained | $25.00 | +22.1% | 08/05/2026 |
Paul Matteis Stifel Nicolaus | Hold | Maintained | $25.00 | +22.1% | 08/05/2026 |
Ritu Baral TD Cowen | Buy | Reiterated | $37.00 | +80.8% | 08/05/2026 |
Uy Ear Mizuho Securities | Buy | Reiterated | $36.00 | +75.9% | 08/04/2026 |
Daniel Giraldo Bank of America Securities | Buy | Reiterated | $30.00 | +46.6% | 07/15/2026 |
Rudy Li Wolfe Research | Buy | Reiterated | $33.00 | +61.2% | 05/06/2026 |
Tessa Romero J.P. Morgan | Buy | Reiterated | $34.00 | +66.1% | 03/04/2026 |
Next call in 39:42:04
Wed, Nov 4, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.18
Revenue / Est. (USD)
- / 332.55M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 278.63M | 283.99M | 268.06M | 307.96M |
Cost of goods sold | 109.48M | 110.98M | 101.66M | 109.87M |
Cost of revenue | 109.48M | 110.98M | 101.66M | 109.87M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 133.40M | 155.62M | 171.02M | 160.25M |
Operating expense | 133.40M | 155.62M | 171.02M | 160.25M |
Total operating expenses | 242.88M | 266.60M | 272.68M | 270.12M |
Operating income | 35.76M | 17.39M | -4.62M | 37.84M |
Other non operating income | 593.00K | 596.00K | 542.00K | 647.00K |
EBT including unusual items | 44.60M | 26.32M | 3.98M | 46.47M |
EBT excluding unusual items | 44.60M | 26.32M | 3.98M | 46.47M |
Income tax expense | -27.18M | -247.25M | 344.00K | 14.97M |
Effective tax rate | -60.96% | -939.43% | 8.64% | 32.22% |
Other operating expenses | - | - | - | - |
Net income | 71.78M | 273.57M | 3.64M | 31.50M |
Net profit margin | 25.76% | 96.33% | 1.36% | 10.23% |
Earnings per share | 0.42 | 0.14 | 0.02 | 0.18 |
Interest and investment income | 8.25M | 8.33M | 8.06M | 7.99M |
Interest expense | - | - | - | - |
Net interest expenses | 8.25M | 8.33M | 8.06M | 7.99M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 38.71M | 20.32M | -1.62M | 40.99M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events